Browsing by Author Gogas, H.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 21 to 26 of 26 < previous 
TitleAuthor(s)Issue date???itemlist.???
Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) studyPentheroudakis, G.; Batistatou, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Bournakis, E.; Eleftheraki, A. G.; Pectasides, D.; Bobos, M.; Papaspirou, I.; Kamina, S.; Gogas, H.; Koutras, A. K.; Pavlidis, N.; Fountzilas, G.24-Nov-2015-
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyFountzilas, G.; Dafni, U.; Dimopoulos, M. A.; Koutras, A.; Skarlos, D.; Papakostas, P.; Gogas, H.; Bafaloukos, D.; Kalogera-Fountzila, A.; Samantas, E.; Briasoulis, E.; Pectasides, D.; Maniadakis, N.; Matsiakou, F.; Aravantinos, G.; Papadimitriou, C.; Karina, M.; Christodoulou, C.; Kosmidis, P.; Kalofonos, H. P.24-Nov-2015-
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survivalKostadima, L.; Pentheroudakis, G.; Fountzilas, G.; Dimopoulos, M.; Pectasides, D.; Gogas, H.; Stropp, U.; Christodoulou, C.; Samantas, E.; Wirtz, R.; Hennig, G.; Bafaloukos, D.; Arapantoni, P.; Kalofonos, H.; Papakostas, P.; Economopoulos, T.; Bamias, A.; Pavlidis, N.24-Nov-2015-
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationChristodoulou, C.; Kostopoulos, I.; Kalofonos, H. P.; Lianos, E.; Bobos, M.; Briasoulis, E.; Gogas, H.; Razis, E.; Skarlos, D. V.; Fountzilas, G.24-Nov-2015-
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialSkarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, A.; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C. A.; Pectasides, D.; Gogas, H.; Aravantinos, G.; Pavlidis, N.; Arapantoni, P.; Skarlos, D. V.; Fountzilas, G.24-Nov-2015-
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology GroupGogas, H.; Bafaloukos, D.; Aravantinos, G.; Fountzilas, G.; Tsoutsos, D.; Panagiotou, P.; Frangia, K.; Kalofonos, H. P.; Briasoulis, E.; Castana, O.; Polyzos, A.; Pectasides, D.; Ioannovich, J.24-Nov-2015-